Pages that link to "Q39089944"
Jump to navigation
Jump to search
The following pages link to Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors (Q39089944):
Displaying 50 items.
- Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment (Q26738359) (← links)
- Targeted therapies and immunotherapy in non-small-cell lung cancer (Q26738986) (← links)
- PD-1/PD-L1 blockades in non-small-cell lung cancer therapy (Q26765024) (← links)
- Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity (Q26769744) (← links)
- Novel technologies and emerging biomarkers for personalized cancer immunotherapy (Q26770780) (← links)
- Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib (Q26775817) (← links)
- Advances in immunotherapy for treatment of lung cancer (Q26778790) (← links)
- Subverting Subversion: A Review on the Breast Cancer Microenvironment and Therapeutic Opportunities (Q26784839) (← links)
- The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients (Q26797478) (← links)
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack (Q26798448) (← links)
- Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints (Q26801551) (← links)
- Predictive biomarkers in precision medicine and drug development against lung cancer (Q26824536) (← links)
- Universes collide: combining immunotherapy with targeted therapy for cancer (Q26825316) (← links)
- Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma (Q26827104) (← links)
- Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer (Q26865779) (← links)
- New immunotherapies targeting the PD-1 pathway (Q27010018) (← links)
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. (Q27853339) (← links)
- The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer (Q28067196) (← links)
- Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment (Q28069424) (← links)
- PD-1 and its ligands are important immune checkpoints in cancer (Q28069485) (← links)
- Checkpoint inhibitors in lung cancer: latest developments and clinical potential (Q28076467) (← links)
- Update on immune checkpoint inhibitors in gynecological cancers (Q28076497) (← links)
- Mechanisms of resistance to EGFR-targeted drugs: lung cancer (Q28077415) (← links)
- Immunosuppression associated with chronic inflammation in the tumor microenvironment (Q28083450) (← links)
- Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer (Q28084766) (← links)
- Nivolumab in melanoma: latest evidence and clinical potential (Q28258598) (← links)
- PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment (Q33275412) (← links)
- The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma (Q33597192) (← links)
- Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor. (Q33607407) (← links)
- The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC. (Q33618747) (← links)
- Molecular pathways and therapeutic targets in lung cancer (Q33688872) (← links)
- Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma (Q33736377) (← links)
- Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy (Q33736664) (← links)
- PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. (Q33839204) (← links)
- Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives (Q33884361) (← links)
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression (Q34417878) (← links)
- Nivolumab in NSCLC: latest evidence and clinical potential (Q34466452) (← links)
- Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer (Q34494115) (← links)
- Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy (Q34522172) (← links)
- PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation (Q34996125) (← links)
- EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy (Q35067875) (← links)
- Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier! (Q35089270) (← links)
- Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma (Q35329190) (← links)
- EGFR: The Paradigm of an Oncogene-Driven Lung Cancer (Q35619241) (← links)
- Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma (Q35624496) (← links)
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients (Q35677709) (← links)
- Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation (Q35681604) (← links)
- Isolation of epithelial, endothelial, and immune cells from lungs of transgenic mice with oncogene-induced lung adenocarcinomas (Q35816386) (← links)
- PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors (Q35824122) (← links)
- Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics (Q35879427) (← links)